Aurobindo Pharma may get USFDA nod for new facility: Sources

MUMBAI: Aurobindo Pharma seems all set to get approval from the USFDA for its new Hyderabad-based Unit IV facility, say sources.

The inspection of the unit, which manufactures injectables, has already been conduction by the USFDA officials between August and September. According to analysts, post approval, the new unit IV will add $30-40 million in sales for the company.

The company is also likely to get clearance for its unit VI, which was facing ban for the past 18 months. The Unit VI manufactures solid dosage formulations. The company’s management refused to comment on the timing of clearance as it is a USFDA matter.

At 01:05 pm, the stock was at Rs 196, up 2.62 per cent, on the BSE. It touched a 52-week high of Rs 197.90 in trade today.